Leica Biosystems and CellCarta Partner to Accelerate Companion Diagnostics Development in China
Suzhou, China - March 26, 2025 - Leica Biosystems, a global leader in anatomic pathology, today announced a strategic partnership with CellCarta, a globally recognized Contract Research Organization laboratory serving the biopharmaceutical industry. This partnership combines Leica Biosystems' cutting-edge anatomic pathology technologies and local manufacturing expertise with CellCarta's superior testing methodologies and development capabilities, all under rigorous quality management systems. The alliance will provide pharmaceutical and biotechnology companies with a comprehensive range of biomarker services in China for China. These services encompass all phases from R&D to market introduction, including exploratory laboratory research, patient screening and enrollment for clinical trials, as well as the registration and marketing of companion diagnostics.
The partnership between Leica Biosystems, its parent company Danaher, and CellCarta will establish Danaher's third Center for Enabling Precision Medicine (CEPM) globally, following the centers in the United States and the United Kingdom. This collaboration brings together innovative synergies across platforms under Danaher and underscores Danaher’s commitment to accelerating local R&D and innovation.
The company also announced the official inauguration of Leica Biosystems (Suzhou) Co., Ltd., located at the Danaher China Medical Diagnostics Platform R&D and Manufacturing Base. In the future, the Suzhou factory will serve as Leica Biosystems’ domestic hub for R&D and production of local reagent products, overseeing the entire lifecycle from early-stage R&D to market launch of these products in China. By leveraging the R&D and production base in Suzhou, Leica Biosystems aims to accelerate the conversion of in vitro diagnostic products from research to commercialization, thereby promoting the advancement of precision medicine in China.
At a ceremony to celebrate the collaboration, Guan Yunyun, General Manager of Leica Biosystems China, stated: "Starting from 2025, the Leica Biosystems Suzhou factory will increase its independent R&D of immunohistochemistry antibodies while expanding companion diagnostics with pharmaceutical partners. This strategic cooperation with CellCarta will accelerate the development and marketing of companion diagnostic solutions and associated new medications. We are witnessing China’s precision medicine sector enter hyperdrive, which will ultimately benefit more cancer patients.”
Echoing this vision, Christopher Ung, Chief Scientific Business Officer of CellCarta, emphasized: "This collaboration goes beyond simply combining resources; it represents a transformative model of cooperation designed to advance precision diagnostics and treatment. CellCarta is committed to China’s rapidly growing precision medicine field, providing world class Contract Research Organization laboratory services to our local customers in China."
This partnership in China will deliver high-quality biomarker testing solutions through accelerated development cycles. By synergizing both parties’ technological strengths, this partnership injects fresh momentum into the advancement of precision medicine, empowering biomedical clients across therapeutic areas with robust diagnostic support from research through commercialization.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in workflow solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture.
About CellCarta
CellCarta is a leading global CRO laboratory to the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides a wide range of biomarker testing services and customized solutions to world-renowned pharmaceutical companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the entire drug development cycle from discovery to late-stage clinical trials.
